ArticleJournal of hematology & oncology2026

Standard-of-care ciltacabtagene autoleucel in earlier versus later lines of therapy for relapsed or refractory multiple myeloma: a nationwide registry analysis.

Nico Gagelmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.